Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
The price of Maravai LifeSciences Holdings Inc (NASDAQ: MRVI) closed at $4.01 in the last session, down -2.43% from day before closing price of $4.11. In other words, the price has decreased by -$2.43 from its previous closing price. On the day, 3.33 million shares were traded.
Ratios:
We take a closer look at MRVI’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 9.94 and its Current Ratio is at 10.74. In the meantime, Its Debt-to-Equity ratio is 1.63 whereas as Long-Term Debt/Eq ratio is at 1.59.
On December 05, 2024, Goldman Downgraded its rating to Sell which previously was Neutral but kept the price unchanged to $4.25.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jan 31 ’25 when ORESHACK KURT sold 25,000 shares for $5.03 per share. The transaction valued at 125,750 led to the insider holds 167,618 shares of the business.
ORESHACK KURT bought 25,000 shares of MRVI for $125,750 on Jan 31 ’25. On Nov 12 ’24, another insider, DeFord John A, who serves as the Director of the company, bought 17,500 shares for $5.75 each. As a result, the insider paid 100,625 and bolstered with 70,046 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 3.66 while its Price-to-Book (P/B) ratio in mrq is 1.65.
Stock Price History:
Over the past 52 weeks, MRVI has reached a high of $11.56, while it has fallen to a 52-week low of $3.93. The 50-Day Moving Average of the stock is -21.16%, while the 200-Day Moving Average is calculated to be -45.35%.
Shares Statistics:
A total of 141.59M shares are outstanding, with a floating share count of 117.88M. Insiders hold about 16.89% of the company’s shares, while institutions hold 87.06% stake in the company.
Earnings Estimates
The company has 15.0 analysts who recommend its stock at the moment. The consensus estimate for the next quarter is -$0.02, with high estimates of $0.0 and low estimates of -$0.06.
Analysts are recommending an EPS of between -$0.06 and -$0.1 for the fiscal current year, implying an average EPS of -$0.08. EPS for the following year is -$0.07, with 15.0 analysts recommending between $0.01 and -$0.2.
Revenue Estimates
According to 12 analysts, the current quarter’s revenue is expected to be $57.79M. It ranges from a high estimate of $60.4M to a low estimate of $56.7M. As of the current estimate, Maravai LifeSciences Holdings Inc’s year-ago sales were $74.14MFor the next quarter, 12 analysts are estimating revenue of $63.62M. There is a high estimate of $72.1M for the next quarter, whereas the lowest estimate is $52M.
A total of 13 analysts have provided revenue estimates for MRVI’s current fiscal year. The highest revenue estimate was $263.2M, while the lowest revenue estimate was $259.5M, resulting in an average revenue estimate of $260.53M. In the same quarter a year ago, actual revenue was $288.94MBased on 16 analysts’ estimates, the company’s revenue will be $267.09M in the next fiscal year. The high estimate is $296.63M and the low estimate is $234.41M.
